Patent · US Active

RBM3 in colorectal cancer prognostics

US8728739B2 · kind B2 · utility

0Cited by

0References

19Claims

0Family size

Assignee

Atlas Antibodies AB · SE

Inventors

Mathias Uhlen · Uppsala, SE
Fredrik Pontén · Uppsala, SE
Karin Jirström · Malmö, SE

Key dates

Filing date	Aug 16, 2011
Grant date	May 20, 2014
Priority date	—
Expiry date	Mar 22, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.